ASH presentations in San Diego
25 Nov 2016
EORTC will be presenting four posters at the American Society of Hematology’s 58th Annual Meeting and Exposition (December 3-6, 2016) in San Diego
Prophylactic CNS Therapy (with or without Radiation Therapy) in Medium-High Risk Acute Lymphoblastic Leukemia (ALL) Children: Long-Term Outcome Evaluation of the Randomized BFM-oriented Trial 58832 (period 1983-1989) of the EORTC Children Leukemia (Abstract: 2775)
Session 612: Acute Lymphoblastic Leukemia: Clinical Studies: Poster II; Sunday 04.12.2016 – 6:00 PM – 8:00 PM
Location: San Diego Convention Center, Hall GH
Authors: Caroline Piette, Stefan Suciu, Yves Bertrand, Anne Uyttebroeck, Els Vandecruys, Geneviève Plat, Patrick Lutz, Claire Pluchart, Nicolas Sirvent, Maryline Poirée, Pauline Simon, Alina Ferster, Claire Hoyoux, Francoise Mazingue, Robert Paulus, Dominique Plantaz, Caroline Thomas, Caroline Gilotay, Jutte Van Der Werff Ten Bosch, Pierre Simon Rohrlich, Yves Benoit
Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials (Abstract: 2847)
Session 617: Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II; Sunday 04.12.2016 – 6:00 PM – 8:00 PM
Location: San Diego Convention Center, Hall GH
Authors: Frédéric Baron*, Marian Stevens-Kroef*, Giovanna Meloni, Petra Muus, Jean-Pierre Marie, Constantijn J.M. Halkes, Xavier Thomas, Radovan Vrhovac, Giorgina Specchia, François Lefrère Sr, Simona Sica, Marco Mancini, Adriano Venditti, Anne Hagemeijer, Joop Jansen, Sergio Amadori, Theo de Witte, Roel Willemze, Stefan Suciu
* Co first authors
Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study (Abstract: 2288)
Session 732: Clinical Allogeneic Transplantation: Results: Poster I; Saturday 03.12.2016 – 5:30 PM – 7:30 PM
Location: San Diego Convention Center, Hall GH
Authors: F. Baron, F. Efficace, L. Cannella, F. Mandelli, R.Willemze, P.Muus, J-P. Marie, D. Ferrero, M. Dictus, P. Fazi, E. La Sala, J-H. Bourhis, F. Fabbiano, A. Bosi, M. Sborgia, G., Martinelli, D. Bron, M. C. Petti, C. J.M. Halkes, W. J.F.M. van der Velden, M. Boccadoro, S. Amadori, R. A. Zittoun and S. Suciu
Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study (Abstract 1743)
Session 618: Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I; Saturday 03.12.2016 — 5:30 PM – 7:30 PM
Location: San Diego Convention Center, Hall GH
Authors: Laura Clement, Stefan Suciu, Isabelle Luquet, Alina Ferster, Karima Yakouben, Anne Uytterbroeck, Catherine Paillard, Nicolas Sirvent, Vitor Costa, Barbara De Moerloose, Francoise Mazingue, Emmanuel Plouvier, Martine Munzer, Maryline Poirée, Odile Minckes, Frédéric Millot, Dominique Plantaz, Caroline Piette, Frank Speleman, Hélène Cavé, Jutte VanderWerff-tenBossch, Pierre Simon Rohrlich, Yves Bertrand, Yves Benoit, Geneviève Plat
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023